ArticleUrolithiasis2026
Real-world efficacy and safety of the CVAC 2.0 ureteroscope: results from a single-center retrospective study.
Article in Urolithiasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The CVAC 2.0 ureteroscope enables simultaneous lasing and suctioning capabilities under direct visual guidance and received FDA clearance for use in lithotripsy procedures in early 2024. We report real-world clinical efficacy and safety data of this novel device. A retrospective cohort study was conducted at a single center where five urologists offered CVAC 2.0 treatment to their patients. Baseline demographic characteristics, procedure factors, complications, stone factors, and stone-free status based on volumetric and single-dimension analysis were collected through chart review. Stones volumes were calculated using the scalene ellipsoid formula and stone complexity was characterized by the modified S.T.O.N.E. score. A total of 61 cases and 106 stones were identified and eligible for volumetric analysis. Mean age was 60, mean BMI was 32, 28% were anticoagulated, and 73% had an ASA score of 3 or higher. Median total pre-operative linear stone burden was 2.2 cm and median volume was 1,003mm
Indexed as
Identifiers
42417984What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.